EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose

S E Alexander, R A Mitchell, A Dunlop, T Herbert, K Morrison, J Nartey, U Oelfke, H A McNair, A C Tree

Clinical and Translational Radiation Oncology · 2025-07 · 53 · 100985

DOI: 10.1016/j.ctro.2025.100985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Radiation Oncology, 2025-07. Verfasst von S E Alexander und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DOD Prostate Cancer Research Program, Royal Marsden NHS Foundation Trust, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Magnetic resonance image-guided adaptive radiotherapy (MRIgART) reduces uncertainties by correcting for day-to-day target and organ-at-risk deformation and motion. This is the first study to examine the dosimetric impact of MRIgART for ultrahypofractionated prostate cancer treatment, compared to standard-of-care image-guided non-adapted radiotherapy.

Methods

Twenty patients with localised prostate cancer, who received ultrahypofractionated MRIgART on the Unity MR linac (Elekta, Sweden) were retrospectively analysed. Online daily MRI was acquired for replanning (MRI session ) and a second for position verification before treatment (MRI verification ). To compare delivered dose with and without adaptation, three plans were generated offline per fraction; a session plan (reference plan adapted to MRI session anatomy), a verification plan (session plan recalculated on MRI verfication anatomy), and a non-adapted plan (reference plan recalculated on MRI verfication anatomy). Target and organ-at-risk doses were calculated, and dose difference evaluated. Secondary analysis, using deformable dose accumulation, estimated verification and non-adapted dose to primary target (CTVpsv) substructures; prostate, gross tumour volume (GTV) and proximal 1 cm of seminal vesicles (1cmSV). Impact of prostate, rectum and bladder volume changes on dose were evaluated.

Results

Median dose to 95 % of the CTVpsv was significantly higher with adaptation; 40.3, 40.0 and 38.2 Gy for session, verification, and non-adapted plans. Adaptation achieved a lower median urethra V42Gy dose but bladder V37Gy dose was lower when not adapting. Rectum V36Gy dose was similar for adapted and non-adapted plans. CTVpsv substructure dose difference was greatest for 1cmSV; 40.0 versus 37.5 Gy for verification/non-adapted plans. Adaptation achieved significantly higher prostate only, but not GTV doses. Prostate and rectal volume changes had a negative impact on non-adapted dose only.

Conclusion

MRIgART, offers significant dosimetric benefit for ultrahypofractionated prostate cancer compared to non-adapted strategies. Greatest benefit is expected for those with SV or high-risk of SV involvement, persistent rectal gas, prostate swelling and for the application of novel dose strategies including GTV dose escalation and non-involved prostate dose de-escalation.

Schlagwörter

Stichwörter der Autor:innen

Adaptive radiotherapyMRI-guided radiotherapyProstate cancerUltrahypofractionated radiotherapy

Autor:innen und Institutionen

  • The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, UK.
  • The Joint Department of physics, the Royal Marsden Hospital and the Institute of Cancer Research, UK.
  • The Royal Marsden NHS Foundation Trust, UK.

Förderung

  • DOD Prostate Cancer Research Program
  • Royal Marsden NHS Foundation Trust
  • Cancer Research UK
  • Royal Marsden Cancer Charity
  • Institute of Cancer Research
  • National Institute for Health and Care Research

Zitieren

APA

Alexander, S. E., Mitchell, R. A., Dunlop, A., Herbert, T., Morrison, K., Nartey, J., Oelfke, U., McNair, H. A., & Tree, A. C. (2025). Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose. Clinical and Translational Radiation Oncology, 53, 100985. https://doi.org/10.1016/j.ctro.2025.100985

Vancouver

Alexander SE, Mitchell RA, Dunlop A, Herbert T, Morrison K, Nartey J, et al. Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose. Clinical and Translational Radiation Oncology. 2025;53:100985. doi:10.1016/j.ctro.2025.100985

BibTeX
@article{Alexander2025,
  author = {Alexander, S E and Mitchell, R A and Dunlop, A and Herbert, T and Morrison, K and Nartey, J and Oelfke, U and McNair, H A and Tree, A C},
  title = {Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2025},
  volume = {53},
  pages = {100985},
  doi = {10.1016/j.ctro.2025.100985}
}
Kostenlos starten →